Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Oncogene|December 8, 2015
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signalingH Cheng, P Liu, C Ohlson, et al.
ESMO Open|June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclibC Corti, A R Martin, P T Kurnia, et al.
ESMO Open|February 11, 2026
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancerA Grinshpun, D Dustin, M Cai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastasesO Metzger Filho, J P Leone, T Li, et al.
ESMO Open|January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2X Qiu, P Tarantino, R Li, et al.
ESMO Open|March 5, 2026
Genomic landscape, immune microenvironment and survival in male versus female breast cancerD Trapani, S K Deshmukh, T Samec, et al.
ESMO Open|July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational studyC Corti, X Chu, P Exman, et al.
ESMO Open|October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancerS Morganti, R J Kusmick, M E Hughes, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Pageof 3